Laboratoire d'Immunologie, Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble Cedex 9, France.
Aix-Marseille Université, Assistance-Publique Hôpitaux de Marseille, Centre de Néphrologie et Transplantation Rénale, Centre Hospitalier Universitaire de la Conception, and Aix-Marseille Université, Vascular Research Center of Marseille, Marseille, France.
Arthritis Care Res (Hoboken). 2018 Aug;70(8):1263-1268. doi: 10.1002/acr.23449. Epub 2018 Jun 21.
Systemic lupus erythematosus (SLE) is a multisystem inflammatory disease characterized by the production of various autoantibodies. The aim of this study was to investigate the presence of anti-ficolin-2 antibodies in SLE patients and to evaluate the association between the levels of these autoantibodies, clinical manifestations, and disease activity.
This is a comparative study using a cohort of 165 SLE patients and 48 healthy subjects. SLE patients were further divided into 2 groups (low disease activity [SLE Disease Activity Index (SLEDAI) score ≤4, n = 88] and high disease activity [SLEDAI score >4, n = 77]). Clinical manifestations were defined according to the physician in charge. Active lupus nephritis (LN) was documented by kidney biopsy. Detection of anti-ficolin-2 antibodies was performed by enzyme-linked immunosorbent assay.
Levels of anti-ficolin-2 autoantibodies were significantly higher in SLE patients as compared to healthy subjects and associated with SLEDAI score. They were found to be positive in 61 of 165 SLE patients (37%). The presence of anti-ficolin-2 antibodies was significantly related only to renal involvement, with a very high prevalence (86%) of anti-ficolin-2 antibodies in SLE patients with active LN. Patients with active proliferative LN had significantly more positive anti-ficolin-2 antibodies than those with nonproliferative LN. The combination of anti-ficolin-2, anti-ficolin-3, and anti-C1q demonstrated a very high specificity (98%) for the diagnosis of active LN.
Our results support the usefulness of anti-ficolin-2 as a complementary serologic biomarker for the diagnosis of active lupus with renal manifestations.
系统性红斑狼疮（SLE）是一种多系统炎症性疾病，其特征是产生各种自身抗体。本研究旨在探讨SLE 患者中抗 ficolin-2 抗体的存在，并评估这些自身抗体的水平与临床表现和疾病活动度之间的关系。
这是一项使用 165 例 SLE 患者和 48 例健康对照者的队列比较研究。SLE 患者进一步分为 2 组（低疾病活动度[SLE 疾病活动指数（SLEDAI）评分≤4，n=88]和高疾病活动度[SLEDAI 评分>4，n=77]）。临床表现根据主管医生定义。通过肾活检确定活动性狼疮肾炎（LN）。通过酶联免疫吸附试验检测抗 ficolin-2 抗体。
与健康对照组相比，SLE 患者的抗 ficolin-2 自身抗体水平显著升高，并与 SLEDAI 评分相关。在 165 例 SLE 患者中，有 61 例（37%）抗 ficolin-2 抗体阳性。抗 ficolin-2 抗体的存在仅与肾脏受累显著相关，在活动性 LN 的 SLE 患者中，抗 ficolin-2 抗体的阳性率非常高（86%）。与非增殖性 LN 患者相比，增殖性 LN 患者的抗 ficolin-2 抗体阳性率显著更高。抗 ficolin-2、抗 ficolin-3 和抗 C1q 的联合检测对活动性 LN 的诊断具有非常高的特异性（98%）。
我们的研究结果支持抗 ficolin-2 作为一种辅助血清学生物标志物用于诊断具有肾脏表现的活动性狼疮的有用性。
Zotero 插件